Related Experiment Video
Updated: Jun 27, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Genes and Their Contribution to Breast Cancer Therapy
Andrea Fernández1, Yasmín Cura-Cuevas2,3, Susana Rojo-Tolosa1,2,4,5
1Pharmacy Service, Pharmacogenetics Unit, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
Pharmaceutics
|June 26, 2026
Summary
Certain genetic variations in CES1 and CDA genes may predict capecitabine treatment effectiveness in breast cancer patients, impacting progression-free survival. Further research is needed for clinical application.
Area of Science:
- Pharmacogenomics
- Oncology
- Molecular Biology
Background:
- Breast cancer (BC) is a leading cause of cancer mortality globally.
- Capecitabine is a common treatment for advanced BC, but response varies significantly between individuals.
- Understanding genetic factors influencing capecitabine efficacy is crucial for personalized treatment.
Purpose of the Study:
- To investigate the association between single-nucleotide polymorphisms (SNPs) in capecitabine bioactivation genes and progression-free survival (PFS) in BC patients.
- To identify potential genetic biomarkers for predicting capecitabine response.
Main Methods:
- An ambispective cohort study involving 85 Caucasian BC patients.
- Analysis of four SNPs in the CES1, CDA, and TYMP genes using real-time PCR with TaqMan® probes.
Main Results:
- The GA genotype of CES1 rs71647871 was significantly associated with shorter PFS (p = 0.010; HR = 7.46).
- The TT genotype of CDA rs602950 was also significantly associated with shorter PFS (p = 0.009; HR = 3.50).
Conclusions:
- CES1 rs71647871 and CDA rs602950 genotypes may serve as predictive biomarkers for capecitabine effectiveness in BC.
- Larger cohort studies are recommended to validate these findings for clinical practice.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...